Big Three Drug Groups Talk Generics, Value-Based Pricing, Beneficiary Cost Sharing With HHS Secretary Price

Updated Story Representatives from the Pharmaceutical Research and Manufacturers of America (PhRMA), the Association for Accessible Medicines (AAM) and the Biotechnology Innovation Organization (BIO) discussed Friday (May 12) drug pricing proposals, including value-based pricing, generic competition and reduced beneficiary cost sharing, with HHS Secretary Tom Price, according to one executive who took part in the meeting. While the three groups often find common ground supporting these ideas in the abstract, they at times push different policies. “We...